Carbapenem-resistant Enterobacterales: a growing threat

Infographic

This infographic highlights how the continued rise of carbapenem-resistant Enterobacterales (CRE) in healthcare settings - and its detection in community settings - will impact the effectiveness of treatments, the delivery of quality and sustainable healthcare and creates a very high risk to patients. It provides context and actions for healthcare and policy makers.

What is the problem? 

Bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae (K. pneumoniae) have increased by 72% since 2019.

Infections with carbapenem-resistant Enterobacterales (CRE) such as K. pneumoniae and Escherichia coli (E. coli) pose a significant threat to patients as they are linked to high mortality.

Several strains of multidrug resistant K. pneumoniae are now even resistant to several antibiotics that have been recently developed to treat CRE. 

New strains of K. pneumoniae combine multidrug resistance with greater ability to cause severe disease, making infections harder to treat and potentially more serious.  

Very few treatment options remain available for patients with infections caused by these bacteria.

Addressing the challenge

Healthcare facilities should ensure staff disinfect hands before and after all patient and environmental contact, strengthen infection prevention and control measures, ensure labs can rapidly detect CRE and preserve the effectiveness of antibiotics through antimicrobial stewardship.

Policymakers should ensure public health agencies conduct surveillance and strengthen national coordination for CRE prevention and control with dedicated resources and actions. 

Download the PNG: Carbapenem-resistant Enterobacterales: a growing threat

Infographic: Carbapenem-resistant Enterobacterales: a growing threat

English (112.79 KB - PNG)
Related files

Download the PDF: Carbapenem-resistant Enterobacterales: a growing threat

English (4.21 MB - PDF)

Read the rapid risk assessment

Cover of the report: "Carbapenem-resistant Enterobacterales – fourth update"
Assessment

The epidemiological situation for carbapenem-resistant Enterobacterales (CRE) is worsening in the EU/EEA, and this is leading to an increasing loss of treatment options. At the same time, the estimated incidence of bloodstream infections (BSIs) by carbapenem-resistant K. pneumoniae for the EU/EEA continues to increase. In this document, ECDC assesses the situation and proposes recommendations to EU/EEA countries. 

Rapid risk assessment: Carbapenem-resistant Enterobacterales, fourth update

English (715.27 KB - PDF)

Read the press release

Read about the campaign and see all the materials